Search

Your search keyword '"Heinz, W.J."' showing total 12 results
Start Over Author "Heinz, W.J." Search Limiters Available in Library Collection
12 results on '"Heinz, W.J."'

1. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)

Author

Rieger, C.T., Liss, B., Mellinghoff, S., Buchheidt, D., Cornely, O.A., Egerer, G., Heinz, W.J., Hentrich, M., Maschmeyer, G., Mayer, K., Sandherr, M., Silling, G., Ullmann, A., Vehreschild, M.J.G.T., von Lilienfeld-Toal, M., Wolf, H.H., and Lehners, N.

Published
2018
Full Text
View/download PDF

2. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Author

Ullmann, A.J., Aguado, J.M., Arikan-Akdagli, S., Denning, D.W., Groll, A.H., Lagrou, K., Lass-Flörl, C., Lewis, R.E., Munoz, P., Verweij, P.E., Warris, A., Ader, F., Akova, M., Arendrup, M.C., Barnes, R.A., Beigelman-Aubry, C., Blot, S., Bouza, E., Brüggemann, R.J.M., Buchheidt, D., Cadranel, J., Castagnola, E., Chakrabarti, A., Cuenca-Estrella, M., Dimopoulos, G., Fortun, J., Gangneux, J.-P., Garbino, J., Heinz, W.J., Herbrecht, R., Heussel, C.P., Kibbler, C.C., Klimko, N., Kullberg, B.J., Lange, C., Lehrnbecher, T., Löffler, J., Lortholary, O., Maertens, J., Marchetti, O., Meis, J.F., Pagano, L., Ribaud, P., Richardson, M., Roilides, E., Ruhnke, M., Sanguinetti, M., Sheppard, D.C., Sinkó, J., Skiada, A., Vehreschild, M.J.G.T., Viscoli, C., and Cornely, O.A.

Published
2018
Full Text
View/download PDF

3. Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.

Author

Maertens, J., Lodewyck, T., Donnelly, J.P., Chantepie, S., Robin, C., Blijlevens, N.M., Turlure, P., Selleslag, D., Baron, F., Aoun, M., Heinz, W.J., Bertz, H., Ráčil, Z., Vandercam, B., Drgona, L., Coiteux, V., Llorente, C.C., Schaefer-Prokop, C.M., Paesmans, M., Ameye, L., Meert, L., Cheung, K.J., Hepler, D.A., Loeffler, J., Barnes, R., Marchetti, O., Verweij, P.E., Lamoth, F., Bochud, P.Y., Schwarzinger, M., Cordonnier, C., Maertens, J., Lodewyck, T., Donnelly, J.P., Chantepie, S., Robin, C., Blijlevens, N.M., Turlure, P., Selleslag, D., Baron, F., Aoun, M., Heinz, W.J., Bertz, H., Ráčil, Z., Vandercam, B., Drgona, L., Coiteux, V., Llorente, C.C., Schaefer-Prokop, C.M., Paesmans, M., Ameye, L., Meert, L., Cheung, K.J., Hepler, D.A., Loeffler, J., Barnes, R., Marchetti, O., Verweij, P.E., Lamoth, F., Bochud, P.Y., Schwarzinger, M., and Cordonnier, C.

Abstract

Item does not contain fulltext, BACKGROUND: Empiric antifungal therapy is considered the standard of care for high-risk neutropenic patients with persistent fever. The impact of a preemptive, diagnostic-driven approach based on galactomannan screening and chest computed tomography scan on demand on survival and on the risk of invasive fungal disease (IFD) during the first weeks of high-risk neutropenia is unknown. METHODS: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and allogeneic hematopoietic cell transplant recipients were randomly assigned to receive caspofungin empirically (arm A) or preemptively (arm B), while receiving fluconazole 400 mg daily prophylactically. The primary end point of this noninferiority study was overall survival (OS) 42 days after randomization. RESULTS: Of 556 patients recruited, 549 were eligible: 275 in arm A and 274 in arm B. Eighty percent of the patients had AML or MDS requiring high-dose chemotherapy, and 93% of them were in the first induction phase. At day 42, the OS was not inferior in arm B (96.7%; 95% confidence interval [CI], 93.8%-98.3%) when compared with arm A (93.1%; 95% CI, 89.3%-95.5%). The rates of IFDs at day 84 were not significantly different, 7.7% (95% CI, 4.5%-10.8%) in arm B vs 6.6% (95% CI, 3.6%-9.5%) in arm A. The rate of patients who received caspofungin was significantly lower in arm B (27%) than in arm A (63%; P < .001). CONCLUSIONS: The preemptive antifungal strategy was safe for high-risk neutropenic patients given fluconazole as prophylaxis, halving the number of patients receiving antifungals without excess mortality or IFDs. Clinical Trials Registration. NCT01288378; EudraCT 2010-020814-27.

Published
2023

4. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study

Author

Boch, T., Spiess, B., Cornely, O.A., Vehreschild, J.J., Rath, P.M., Steinmann, J., Heinz, W.J., Hahn, J., Krause, S.W., Kiehl, M.G., Egerer, G., Liebregts, T., Koldehoff, M., Klein, M., Nolte, F., Mueller, M.C., Merker, N., Will, S., Mossner, M., Popp, H., Hofmann, W.-K., Reinwald, M., and Buchheidt, D.

Published
2016
Full Text
View/download PDF

6. Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative

Author

White, P.L., Barnes, R.A., Springer, J., Klingspor, L., Cuenca-Estrella, M., Morton, C.O., Lagrou, K., Bretagne, S., Melchers, W.J.G., Mengoli, C., Donnelly, J.P., Heinz, W.J., and Loeffler, J.

Subjects
Adult, Male, Microbiology (medical), medicine.medical_specialty, Time Factors, Mycology, Aspergillosis, Polymerase Chain Reaction, Sensitivity and Specificity, Gastroenterology, Specimen Handling, law.invention, Plasma, Young Adult, 03 medical and health sciences, law, Internal medicine, medicine, Humans, DNA, Fungal, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Polymerase chain reaction, Aged, Retrospective Studies, 030304 developmental biology, 0303 health sciences, Aspergillus, Hematology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], biology, 030306 microbiology, Clinical performance, Case-control study, Cancer, Retrospective cohort study, Middle Aged, biology.organism_classification, medicine.disease, QR, 3. Good health, Molecular Diagnostic Techniques, Case-Control Studies, Immunology, Female, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Aspergillus PCR testing of serum provides technical simplicity but with potentially reduced sensitivity compared to whole-blood testing. With diseases for which screening to exclude disease represents an optimal strategy, sensitivity is paramount. The associated analytical study confirmed that DNA concentrations were greater in plasma than those in serum. The aim of the current investigation was to confirm analytical findings by comparing the performance of Aspergillus PCR testing of plasma and serum in the clinical setting. Standardized Aspergillus PCR was performed on plasma and serum samples concurrently obtained from hematology patients in a multicenter retrospective anonymous case-control study, with cases diagnosed according to European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (19 proven/probable cases and 42 controls). Clinical performance and clinical utility (time to positivity) were calculated for both kinds of samples. The sensitivity and specificity for Aspergillus PCR when testing serum were 68.4% and 76.2%, respectively, and for plasma, they were 94.7% and 83.3%, respectively. Eighty-five percent of serum and plasma PCR results were concordant. On average, plasma PCR was positive 16.8 days before diagnosis and was the earliest indicator of infection in 13 cases, combined with other biomarkers in five cases. On average, serum PCR was positive 10.8 days before diagnosis and was the earliest indicator of infection in six cases, combined with other biomarkers in three cases. These results confirm the analytical finding that the sensitivity of Aspergillus PCR using plasma is superior to that using serum. PCR positivity occurs earlier when testing plasma and provides sufficient sensitivity for the screening of invasive aspergillosis while maintaining methodological simplicity.

Published
2015

8. Etravirin Serum-Konzentrationen in der antiretroviralen Kombinations-Therapie der HIV-Infektion

Author

Röckl, T., Heinz, W.J., Schirmer, D., Kuhn, A., Zirkel, J., Daubitz, T., Langmann, P., and Klinker, H.

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund: Etravirin (TMC 125) ist ein neuer nicht-nukleosidischer Reverse Transcriptase Inhibitor (NNRTI), für welchen gute klinische Aktivität sowohl gegenüber Wildtyp HI-Virus als auch bei einigen typischen erworbenen NNRTI-Mutationen belegt werden konnte. Die Pharmakokinetik wird[for full text, please go to the a.m. URL], 10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Published
2010
Full Text
View/download PDF

9. Improvement in the outcome of invasive fusariosis in the last decade

Author

Nucci, M., primary, Marr, K.A., additional, Vehreschild, M.J.G.T., additional, de Souza, C.A., additional, Velasco, E., additional, Cappellano, P., additional, Carlesse, F., additional, Queiroz-Telles, F., additional, Sheppard, D.C., additional, Kindo, A., additional, Cesaro, S., additional, Hamerschlak, N., additional, Solza, C., additional, Heinz, W.J., additional, Schaller, M., additional, Atalla, A., additional, Arikan-Akdagli, S., additional, Bertz, H., additional, Galvão Castro, C., additional, Herbrecht, R., additional, Hoenigl, M., additional, Härter, G., additional, Hermansen, N.E.U., additional, Josting, A., additional, Pagano, L., additional, Salles, M.J.C., additional, Mossad, S.B., additional, Ogunc, D., additional, Pasqualotto, A.C., additional, Araujo, V., additional, Troke, P.F., additional, Lortholary, O., additional, Comely, O.A., additional, and Anaissie, E., additional

Published
2014
Full Text
View/download PDF

11. Fungiscope - state of affairs

Author

Vehreschild, M.J.G.T., Heinz, W.J., Hamprecht, A., Fischer, G., de Hoog, S., Vehreschild, J.J., Cornely, O.A., Vehreschild, M.J.G.T., Heinz, W.J., Hamprecht, A., Fischer, G., de Hoog, S., Vehreschild, J.J., and Cornely, O.A.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results